Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2003
06/17/2003US6579885 For therapy of attention deficit disorder, hyperactivity disorder, anxiety, depression, post-traumatic stress disorder, supranuclear palsy, eating disorders, obsessive compulsive disorder, analgesia, nicotine addiction, Parkinsonism
06/17/2003US6579884 Gastrointestinal inflammatory diseases, antisecretory; infection by Helicobacter pylori of human gastric mucosa; Substituted imidazo(1,2-a)pyridines
06/17/2003US6579883 Fluorinated 3,4-dihydroquinoline derivatives used as NOS inhibitors
06/17/2003US6579881 Muscle relaxants, antiserotonine agent
06/17/2003US6579879 For therapy of diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic microangiopathy and diabetic macroangiopathy in mammals
06/17/2003US6579877 Combination of benzoquinazoline antifolates and protecting agents
06/17/2003US6579875 Triazolo-pyridazine derivatives as ligands for GABA receptors
06/17/2003US6579874 Substituted azoles
06/17/2003US6579873 Treatment of inflammation, arthritis, bone disorders, respiratory system disorders
06/17/2003US6579872 Bezamide derivatives for the treatment of diseases mediated by cytokines
06/17/2003US6579870 5-(1,4-diazepan-1-yl)-2-((3 -fluorophenyl)sulfonyl)phenylamine for example; treatment of diseases or disorders of the central nervous system; modulation of serotonin (5-HT) activity
06/17/2003US6579869 Cephalotaxanes: their method of preparation and their use in treatment of cancers, leukemias, parasites, including those resistant to usual chemotherapeutic agents, and as reversal agents
06/17/2003US6579868 Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
06/17/2003US6579867 Azepin-2-one derivatives useful for treating Alzheimer's disease
06/17/2003US6579866 Composition and method for modulating nutrient partitioning
06/17/2003US6579865 For use in transdermally and topically applied drug delivery
06/17/2003US6579864 Arthritic diseases and/or autoimmune diseases
06/17/2003US6579863 Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
06/17/2003US6579861 Administering alpha -hydroxy-2-methylene-19-nor-homopregnacalciferol for therapy of psoriasis
06/17/2003US6579860 Interleukin-6 production inhibitors
06/17/2003US6579859 Administering Tetraalkylphosphonium salt
06/17/2003US6579858 Use of low-molecular-weight heparins for the prevention and treatment of cerebral edemas
06/17/2003US6579856 Inhibition of stress activated protein kinase (SAPK) pathway and sensitization of cells to cancer therapies
06/17/2003US6579855 Adenovirus-mediated gene therapy
06/17/2003US6579854 Diagnosis and management of infection caused by chlamydia
06/17/2003US6579853 For inhibiting apoptosis or apoptosis-like cell death
06/17/2003US6579711 Lactic acid bacteria species
06/17/2003US6579695 Phosphopantetheinyl transferases and uses thereof
06/17/2003US6579545 Providing chewing gum cores; providing a coating syrup comprising a bulk sweetener; providing antigas agent; applying antigas agent and coating syrup to cores and drying syrup to produce a coating on cores, coating containing antigas agent
06/17/2003US6579544 Blends of vitamins, minerals, carotenoids, flavinoids, glucosamine, chondroitin sulfate, lipoic acid/-A/, coenzyme Q10 and linseed oils for preventing diseases such as degenerative joint disease
06/17/2003US6579540 Administering bis/maltolato/oxovanadium for prophylaxis of tisssue injuries or traumas
06/17/2003US6579536 Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
06/17/2003US6579534 Mixture of soy protein and isoflavone
06/17/2003US6579533 Bioabsorbable drug delivery system for local treatment and prevention of infections
06/17/2003US6579521 Methods of therapy for HIV infection
06/17/2003US6579519 For therapy of eye infections such as conjunctivitis, blepharitis, keratitis sicca etc and to provide intraocular treatment through the cornea for diseases such as glaucoma or uveitis
06/17/2003US6579512 Topical steroid spray
06/17/2003CA2307553C Citrus peel extract as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases
06/17/2003CA2291133C Method for the preparation of citalopram
06/17/2003CA2290973C Encapsulated solution dosage forms of sertraline
06/17/2003CA2279099C New 8h-thieno-[2,3-b]pyrrolizine-8-one derivatives, their preparation process, and pharmaceutical compositions containing these derivatives
06/17/2003CA2232410C Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
06/17/2003CA2228472C Tablets containing anion exchange resin
06/17/2003CA2226422C Use of indigestible oligosaccharides to prevent and treat diarrhea
06/17/2003CA2220698C N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same
06/17/2003CA2198245C Methods and means for drug administration
06/17/2003CA2183472C Liquid paraffin oil and lactulose-based hypocaloric laxative jelly and method for its preparation
06/17/2003CA2178722C Methods for sedating and anaesthetising aquatic organisms
06/17/2003CA2141803C Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen
06/17/2003CA2118114C Potentiation of antimicrobial effects
06/17/2003CA2096020C 2.beta.,19-methyleneamino bridged steroids as aromatase inhibitors
06/17/2003CA2094030C A method for drug formulation and a pharmaceutical composition
06/17/2003CA2088163C Liposomes that provide thymic dependent help to weak vaccine antigens
06/14/2003CA2412713A1 Dextromethorphan tannate
06/14/2003CA2412464A1 Dextromethorphan tannate
06/14/2003CA2412463A1 Dextrochlorpheniramine tannate
06/14/2003CA2364985A1 Imidazo(2,1-b)thiadiazole sulfonamides
06/13/2003WO2003047602A1 Immunostimulatory oligodeoxynucleotides
06/13/2003CA2452909A1 Immunostimulatory oligodeoxynucleotides
06/12/2003WO2003048775A2 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases
06/12/2003WO2003048773A2 Methods for monitoring amyotrophic lateral sclerosis
06/12/2003WO2003048383A2 Effectors of innate immunity
06/12/2003WO2003048379A1 T-bet compositions and methods of use thereof
06/12/2003WO2003048375A1 Hybrid glycosylated products and their production and use
06/12/2003WO2003048373A1 Novel substance fki-0550 and process for producing the same
06/12/2003WO2003048298A2 Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
06/12/2003WO2003048209A1 Bispecific anti-cd19 x anti-cd16 antibodies and uses thereof
06/12/2003WO2003048205A2 Novel proteins with il-6 inhibiting activity
06/12/2003WO2003048184A2 Flavivirus ns1 subunit vaccine
06/12/2003WO2003048183A2 Method for obtaining oestrogen from mare urine
06/12/2003WO2003048182A1 Use of totle saponins compounds and a pharmaceutical composition containing totle saponins compounds
06/12/2003WO2003048180A1 Crystalline form of a ribofuranosyluronamide derivative; a human adenosine a2a receptor agonist
06/12/2003WO2003048168A2 Trioxane derivatives as antimalaria or anticancer compounds
06/12/2003WO2003048167A1 Trioxane derivatives
06/12/2003WO2003048166A1 Podophyllotoxins as antiproliferative agents
06/12/2003WO2003048165A1 ADENOSINE A2a RECEPTOR ANTAGONISTS
06/12/2003WO2003048164A2 Adenosine a2a receptor antagonists
06/12/2003WO2003048163A1 [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS
06/12/2003WO2003048162A1 Novel crystalline compound
06/12/2003WO2003048160A1 Ring fused pyrazole derivatives
06/12/2003WO2003048158A1 Glycinamides as factor xa inhibitors
06/12/2003WO2003048156A1 Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine
06/12/2003WO2003048155A1 Thrombin inhibitors
06/12/2003WO2003048154A1 4-(piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as urotensin ii receptor antagonists
06/12/2003WO2003048153A1 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
06/12/2003WO2003048152A2 Inflammation modulators
06/12/2003WO2003048150A1 Substituted 5-membered n-heterocyclic compounds and their uses for treating or preventing neurodegenerative diseases
06/12/2003WO2003048149A1 Processing method of lactonization in the preparation of statins
06/12/2003WO2003048148A2 Statin-like compounds
06/12/2003WO2003048147A2 PREPARATION OF CIS-FUSED 3,3a,8,12b-TETRAHYDRO-2H-DIBENZO[3,4:6,7]CYCLOHEPTA[1,2-b]FURAN DERIVATIVES
06/12/2003WO2003048146A1 PREPARATION OF TRANS-FUSED 3,3a,8,12b-TETRAHYDRO-2H-DIBENZO[3,4:6,7]CYCLOHEPTA[1,2-b]FURAN DERIVATIVES
06/12/2003WO2003048141A1 Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof
06/12/2003WO2003048140A1 Azole compound and medicinal use thereof
06/12/2003WO2003048139A1 Novel inhibitor compounds specific of secreted non-pancreatic human a2 phospholipase of group ii
06/12/2003WO2003048137A1 Metabotropic glutamate receptor-5 modulators
06/12/2003WO2003048136A1 Cyclopropyl hexane containing oxazolidinone antibiotics and derivatives thereof
06/12/2003WO2003048135A1 Amorphous and crystalline forms of losartan potassium and process for their preparation
06/12/2003WO2003048134A1 Triazole compound and medicinal use thereof
06/12/2003WO2003048133A1 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)
06/12/2003WO2003048132A1 Imidazopyridines, pyrimidines and triazines for enhancing cognition as gaba-a alpha 5 receptor subtype ligands
1 ... 5436 5437 5438 5439 5440 5441 5442 5443 5444 5445 5446 5447 5448 5449 5450 5451 5452 5453 5454 5455 5456 ... 7860